# Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients

Source: https://onco.cc/trials/nct06212076/  
OnCo record `nct06212076` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IPG1094 in advanced solid tumours, run by Nanjing Immunophage Biotech Co., Ltd, now recruiting.

## Summary

Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients is a phase 1/2 interventional study registered as NCT06212076 by Nanjing Immunophage Biotech Co., Ltd, with 60 participants planned, started 2024-07-11 and due to reach its primary completion in 2027-07-09. Interventions recorded: IPG1094.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06212076
- Phase: 1/2
- Setting: A Phase I/II, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Characteristics and Initial Anti-tumor Activity of IPG1094 in Patients With Advanced Solid Tumors
- Sponsor: Nanjing Immunophage Biotech Co., Ltd
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06212076: https://clinicaltrials.gov/study/NCT06212076

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Nanjing Immunophage Biotech](https://onco.cc/companies/nanjing-immunophage-biotech/)
- drugs: [IPG1094](https://onco.cc/drugs/ipg1094/)

---
JSON: https://onco.cc/api/v1/entities/nct06212076.json